Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Subfoveal Neovascular Age-Related Macular Degeneration”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Testing effectiveness (Phase 2)Ended earlyNCT01025232
What this trial is testing

Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

Who this might be right for
Age Related Macular DegenerationChoroidal Neovascular MembraneSubfoveal Neovascular Age-Related Macular Degeneration+2 more
David M. Brown, M.D. 88
Post-approval studies (Phase 4)Study completedNCT05269966
What this trial is testing

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
Novartis Pharmaceuticals 105
Large-scale testing (Phase 3)Ended earlyNCT01944839
What this trial is testing

Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Who this might be right for
Age-Related Macular Degeneration
Ophthotech Corporation 619
Early research (Phase 1)Study completedNCT02591914
What this trial is testing

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Retinal Consultants of Arizona 30
Post-approval studies (Phase 4)Ended earlyNCT00312351
What this trial is testing

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Eyetech Pharmaceuticals 262
Large-scale testing (Phase 3)Study completedNCT00051129
What this trial is testing

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular DegenerationMaculopathy, Age-RelatedAge-Related Maculopathies+2 more
Alcon Research 291
Large-scale testing (Phase 3)Study completedNCT00090623
What this trial is testing

RhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Genentech, Inc. 180
Large-scale testing (Phase 3)Study completedNCT00058994
What this trial is testing

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

Who this might be right for
Macular DegenerationMaculopathy, Age-Related
Alcon Research
Testing effectiveness (Phase 2)Study completedNCT00574093
What this trial is testing

Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD

Who this might be right for
Neovascular Age Related Macular Degeneration
Fondazione G.B. Bietti, IRCCS 15
Large-scale testing (Phase 3)Ended earlyNCT01940900
What this trial is testing

Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Who this might be right for
Age-Related Macular Degeneration
Ophthotech Corporation 627
Large-scale testing (Phase 3)Study completedNCT00056836
What this trial is testing

Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration

Who this might be right for
Macular Degeneration
Genentech, Inc. 720
Early research (Phase 1)UnknownNCT02613559
What this trial is testing

Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
Jiangsu T-Mab Biopharma Co.,Ltd 27
Large-scale testing (Phase 3)Study completedNCT03834753
What this trial is testing

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Who this might be right for
Age-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration
Outlook Therapeutics, Inc. 228
Large-scale testing (Phase 3)Ended earlyNCT01940887
What this trial is testing

Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Who this might be right for
Age-Related Macular Degeneration
Ophthotech Corporation 645
Large-scale testing (Phase 3)Study completedNCT00061594
What this trial is testing

Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

Who this might be right for
Macular Degeneration
Genentech, Inc. 426
Large-scale testing (Phase 3)Study completedNCT04597632
What this trial is testing

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 248
Large-scale testing (Phase 3)Study completedNCT00891735
What this trial is testing

Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

Who this might be right for
Age-related Macular Degeneration
Genentech, Inc. 1,097
Large-scale testing (Phase 3)Study completedNCT03844074
What this trial is testing

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Who this might be right for
Age-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration
Outlook Therapeutics, Inc. 61
Testing effectiveness (Phase 2)UnknownNCT02599064
What this trial is testing

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Who this might be right for
Age-related Macular DegenerationSubfoveal Choroidal NeovascularizationSubretinal Scarring+1 more
RXi Pharmaceuticals, Corp. 9
Load More Results